Virtual research visits in individuals with Parkinson disease enrolled in a clinical trial: REACT-PD Study Interim Analysis
Objective: To demonstrate the feasibility, reliability, and value of conducting web-based clinical trial assessments in individuals with Parkinson disease (PD). Background: Increasing interest has been…Multi-modal retention in a phase III clinical trial in early Parkinson disease (STEADY-PD III)
Objective: To evaluate novel retention strategies in an ongoing phase 3 clinical trial in individuals with Parkinson disease (PD) Background: Adequate participant retention is a…Drug utilization characteristics in individuals with early Parkinson’s disease interim analysis of the STEADY-PD III study
Objective: To review symptomatic therapy (ST) utilization trends in individuals with early Parkinson’s disease (PD). Background: There are changing trends in ST utilization in early…Case study: Real-time MRI articulatory comparison of a congenital aglossic and normal speaker
Objective: Congenital aglossia is a rare syndrome of born without a tongue. This paper examines articulatory movements of a congenital aglossic speaker to understand physiology by…The Critical Path for Parkinson’s Consortium: Understanding Motor Disease Progression Through Quantitative Medicine
Objective: Develop a quantitative tool to optimize the definition of entry criteria, enrichment strategies and stratification approaches, and submit for formal regulatory endorsement at FDA…Treatable Rare Movement Disorders
Objective: To classify therapies of RMD into enzyme replacement therapy, specific dietary changes, avoidance or management of certain triggers, and others Background: Rare diseases (RD)…Disease-modifying effect of Zonisamide with the induction of BDNF and TrkB expression
Objective: To evaluate to predictors of the disease-modifying effect of drugs on Parkinson’s disease (DM-PD) according to long-term therapeutic investigation, especially regarding the non-dopaminergic agent…Development of a prototype alpha-synuclein vaccine to induce T regulatory cells for the treatment of synucleonopathy
Objective: Test the hypothesis that combining humoral and immunosuppressive cellular asyn immunization will enhance asyn clearance, and reduce inflammation and neuropathological symptoms in a human…Results From a Phase 1b Multiple Ascending-Dose Study of PRX002, an Anti–Alpha-Synuclein Monoclonal Antibody, in Patients with Parkinson’s Disease
Objective: To evaluate PRX002 in patients with PD in a double-blind, placebo-controlled, phase 1b multiple ascending-dose study. Background: PRX002 (RG7935) is an investigational monoclonal antibody…Targeting alpha-Synuclein Aggregation for the Treatment of Parkinson’s Disease
Objective: To develop small molecular weight compounds (SMEs) as disease-modifying agents, which are designed to arrest or even reverse the aggregation process of alpha-synuclein (aSyn)…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.